Cargando…

Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia

BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium meas...

Descripción completa

Detalles Bibliográficos
Autores principales: Krogager, Maria Lukács, Søgaard, Peter, Torp‐Pedersen, Christian, Bøggild, Henrik, Gislason, Gunnar, Kragholm, Kristian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955366/
https://www.ncbi.nlm.nih.gov/pubmed/33317370
http://dx.doi.org/10.1161/JAHA.120.017087
_version_ 1783664235782340608
author Krogager, Maria Lukács
Søgaard, Peter
Torp‐Pedersen, Christian
Bøggild, Henrik
Gislason, Gunnar
Kragholm, Kristian
author_facet Krogager, Maria Lukács
Søgaard, Peter
Torp‐Pedersen, Christian
Bøggild, Henrik
Gislason, Gunnar
Kragholm, Kristian
author_sort Krogager, Maria Lukács
collection PubMed
description BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium measurement ≥4.7 mmol/L (hyperkalemia) within 100 days of combination antihypertensive therapy initiation. A second potassium was measured 6 to 100 days after the episode of hyperkalemia. All‐cause mortality within 90 days of the second potassium measurement was assessed using Cox regression. Mortality was examined for 8 predefined potassium intervals derived from the second measurement: 2.2 to 2.9 mmol/L (n=37), 3.0 to 3.4 mmol/L (n=184), 3.5 to 3.7 mmol/L (n=325), 3.8 to 4.0 mmol/L (n=791), 4.1 to 4.6 mmol/L (n=3533, reference), 4.7 to 5.0 mmol/L (n=1786), 5.1 to 5.5 mmol/L (n=720), and 5.6 to 7.8 mmol/L (n=244). Ninety‐day mortality in the 8 strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, respectively. The multivariable analysis showed that patients with concentrations >5.5 mmol/L after an episode of hyperkalemia had increased mortality risk compared with the reference (hazard ratio [HR], 2.27; 95% CI, 1.60–3.20; P<0.001). Potassium intervals 3.5 to 3.7 mmol/L and 3.8 to 4.0 mmol/L were also associated with increased risk of death (HR, 1.71; 95% CI, 1.23–2.37; P<0.001; HR, 1.36; 95% CI, 1.04–1.76; P<0.001, respectively) compared with the reference group. We observed a trend toward increased risk of death within the interval 5.1 to 5.5 mmol/L (HR, 1.29; 95% CI, 0.98–1.69). Potassium concentrations <4.1 mmol/L and >5.0 mmol/L were associated with increased risk of cardiovascular death. CONCLUSIONS: Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased all‐cause and cardiovascular mortality. Potassium concentrations >5.5 mmol/L were also associated with an increased all‐cause and cardiovascular mortality.
format Online
Article
Text
id pubmed-7955366
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79553662021-03-17 Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia Krogager, Maria Lukács Søgaard, Peter Torp‐Pedersen, Christian Bøggild, Henrik Gislason, Gunnar Kragholm, Kristian J Am Heart Assoc Original Research BACKGROUND: Hyperkalemia can be harmful, but the effect of correcting hyperkalemia is sparsely studied. We used nationwide data to examine hyperkalemia follow‐up in patients with hypertension. METHODS AND RESULTS: We identified 7620 patients with hypertension, who had the first plasma potassium measurement ≥4.7 mmol/L (hyperkalemia) within 100 days of combination antihypertensive therapy initiation. A second potassium was measured 6 to 100 days after the episode of hyperkalemia. All‐cause mortality within 90 days of the second potassium measurement was assessed using Cox regression. Mortality was examined for 8 predefined potassium intervals derived from the second measurement: 2.2 to 2.9 mmol/L (n=37), 3.0 to 3.4 mmol/L (n=184), 3.5 to 3.7 mmol/L (n=325), 3.8 to 4.0 mmol/L (n=791), 4.1 to 4.6 mmol/L (n=3533, reference), 4.7 to 5.0 mmol/L (n=1786), 5.1 to 5.5 mmol/L (n=720), and 5.6 to 7.8 mmol/L (n=244). Ninety‐day mortality in the 8 strata was 37.8%, 21.2%, 14.5%, 9.6%, 6.3%, 6.2%, 10.0%, and 16.4%, respectively. The multivariable analysis showed that patients with concentrations >5.5 mmol/L after an episode of hyperkalemia had increased mortality risk compared with the reference (hazard ratio [HR], 2.27; 95% CI, 1.60–3.20; P<0.001). Potassium intervals 3.5 to 3.7 mmol/L and 3.8 to 4.0 mmol/L were also associated with increased risk of death (HR, 1.71; 95% CI, 1.23–2.37; P<0.001; HR, 1.36; 95% CI, 1.04–1.76; P<0.001, respectively) compared with the reference group. We observed a trend toward increased risk of death within the interval 5.1 to 5.5 mmol/L (HR, 1.29; 95% CI, 0.98–1.69). Potassium concentrations <4.1 mmol/L and >5.0 mmol/L were associated with increased risk of cardiovascular death. CONCLUSIONS: Overcorrection of hyperkalemia to levels <4.1 mmol/L was frequent and associated with increased all‐cause and cardiovascular mortality. Potassium concentrations >5.5 mmol/L were also associated with an increased all‐cause and cardiovascular mortality. John Wiley and Sons Inc. 2020-12-02 /pmc/articles/PMC7955366/ /pubmed/33317370 http://dx.doi.org/10.1161/JAHA.120.017087 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Krogager, Maria Lukács
Søgaard, Peter
Torp‐Pedersen, Christian
Bøggild, Henrik
Gislason, Gunnar
Kragholm, Kristian
Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title_full Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title_fullStr Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title_full_unstemmed Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title_short Impact of Plasma Potassium Normalization on Short‐Term Mortality in Patients With Hypertension and Hyperkalemia
title_sort impact of plasma potassium normalization on short‐term mortality in patients with hypertension and hyperkalemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955366/
https://www.ncbi.nlm.nih.gov/pubmed/33317370
http://dx.doi.org/10.1161/JAHA.120.017087
work_keys_str_mv AT krogagermarialukacs impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia
AT søgaardpeter impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia
AT torppedersenchristian impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia
AT bøggildhenrik impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia
AT gislasongunnar impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia
AT kragholmkristian impactofplasmapotassiumnormalizationonshorttermmortalityinpatientswithhypertensionandhyperkalemia